Definitive Contract 75N91022C00018
Award Date 9/15/22
Potential Completion Date 3/14/25
Potential Value $455K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Minneapolis, MN 55410, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
17
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a Direct to Phase II Small Business Innovation Research (SBIR) Concept Award issued by the National Cancer Institute (NCI), a civilian federal agency, to Continuity Biosciences, LLC, a small business located in Bradenton, Florida. The $2,995,581 firm-fixed-price contract is for the development of a novel iontophoretic drug delivery device for the local and effective treatment of oral cancer. The award has a completion date of September 4, 2027. As an SBIR Phase II contract, this...
- <p>The National Cancer Institute (NCI), a civilian federal agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a for-profit subchapter S corporation. The $224,687.00 firm-fixed-price contract, awarded on September 19, 2016, is for the SBIR PHASE I TOPIC 352 CELL-BASED MODELS FOR PROSTATE CANCER HEALTH DISPARITY RESEARCH project, with a planned completion date of June 18, 2017. This contract was set aside for small businesses.</p>
- The U.S. National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Celldex Therapeutics, Inc. in the amount of $199,398.00 on September 20, 2012. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a firm fixed price pricing type. The contract has an ultimate completion date of August 23, 2013. This SBIR Phase I award supports basic research and development activities at Celldex Therapeutics, a for-profit small...
- The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded a $223,412 Small Business Innovation Research (SBIR) Program Phase I contract to Qrono, Inc. for the development of a "Failed Tubulin Inhibitor Reformulated as Localized Adjuvant Therapy for Head and Neck Cancer." This Firm Fixed Price contract with a completion date of September 30, 2015 aims to advance an innovative approach to treating head and neck cancer by reformulating a...
- The National Cancer Institute (NCI) awarded a $353,102 Firm Fixed Price contract to Angstrom Research Inc., a self-certified small disadvantaged business, for a Phase I SBIR (Small Business Innovation Research) Concept Award. The contract, identified as 75N91024C00012, is part of the NCI's SBIR program and is focused on the development of innovative therapeutic technologies, devices, or diagnostics for the treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. This is a...
- <p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Oncotherapeutica, Inc. for the development of a "Prostate Cancer Selective Radioactive Prodrug". This $298,882 Firm Fixed Price contract was awarded on September 19, 2016 and has a completion date of November 18, 2017. The contract is designated as a Total Small Business set-aside.</p>
- This is a Small Business Innovation Research (SBIR) Concept Award from the National Cancer Institute (NCI) to Dclk1 LLC, a small business, for the development of nanosponge-linked DCLK1 inhibitors for the targeted treatment of cholangiocarcinoma, a rare cancer. The award has a ceiling value of $353,412 and a performance period ending on December 31, 2024. This award is part of the NCI's SBIR Innovative Concept Award Program, which aims to fund the development of innovative therapeutic...
- <p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanoscale Corporation for the development of a rapid in vitro screening assay to detect cancer biomarkers in urine and blood. The $150,000.00 firm-fixed-price contract has a completion date of May 2, 2013. This SBIR contract is part of the NCI's efforts to support small businesses in the development of innovative cancer-related technologies.</p>
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Nomocan Pharmaceuticals LLC, a for-profit limited liability company, for $354,959. The contract is for the development of a therapeutic technology, device, or diagnostic technology to treat, detect, or diagnose pediatric cancers and rare cancers with survival rates below 50%. The contract has a firm fixed-price pricing type...
- This is a Small Business Innovation Research (SBIR) Concept Award issued by the National Cancer Institute, a civilian agency, for the development of therapeutic or preventative technologies to treat or prevent pediatric cancers and/or rare cancers. The $354,957.00 Firm Fixed Price contract was awarded to Metaclipse Therapeutics Corp, a self-certified small disadvantaged business, on September 5, 2025, with a completion date of September 4, 2026. The contract is set aside for total small business...